Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 5, 2025The Journal of Dermatology

Tissue Eosinophil Counts: A Promising Marker for Optimizing Omalizumab Treatment in Bullous Pemphigoid

View Full Paper
Ask AI
Bookmark
Share

Authors

GAGülfem AkinSASevgi AkarsuCACeylan Avcı

Discussion

Loading...

Member takes

Overview

Retrospective analysis of 27 BP patients assessed omalizumab efficacy and explored tissue eosinophil counts, suggesting a potential predictive marker.

Key Points

  • Tissue eosinophil counts may predict omalizumab response in bullous pemphigoid.
  • Complete remission was achieved in 63% of patients after treatment with omalizumab.
  • The analysis involved 27 patients treated at a single center, focusing on treatment response correlations.
  • While side effects were minimal, the small sample size necessitates further research to validate findings.

Cite This Study

Akin et al. (2025) studied this question.

synapsesocial.com/papers/68bb3d552b87ece8dc95615ehttps://doi.org/10.1111/1346-8138.17932
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Omalizumab in the treatment of bullous pemphigoid: A single-center series of 15 cases2024 · 1 citations
  2. 2Efficacy of omalizumab for the treatment of bullous pemphigoid: Spanish multicentre real-world experience2024 · 8 citations
  3. 3Omalizumab for the Treatment of Bullous Pemphigoid: A Single Center Experience2024
  4. 4Biomarker Predictors of Clinical Efficacy of the Anti-IgE Biologic Omalizumab in Severe Asthma in Adults: Results of the SoMOSA Study2024 · 25 citations
  5. 5Low Total IgE Predicts Non-Response to Omalizumab in Chronic Spontaneous Urticaria: A 10-Year Real-Life Study2025